Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar:604:110402.
doi: 10.1016/j.virol.2025.110402. Epub 2025 Jan 20.

Galectin-8 and GEL01 as potential adjuvants to enhance the immune response induced by a DNA vaccine against bovine alphaherpesvirus Type-1

Affiliations

Galectin-8 and GEL01 as potential adjuvants to enhance the immune response induced by a DNA vaccine against bovine alphaherpesvirus Type-1

Claudia Alejandra Kornuta et al. Virology. 2025 Mar.

Abstract

Bovine alphaherpesvirus-1 (BoAHV-1) causes several symptoms in cattle, leading to significant costs for the livestock industry. In this study, we used a plasmid encoding a secreted form of BoAHV-1 glycoprotein D (pCIgD) as a DNA vaccine. To enhance the potency of the pCIgD vaccine, we used Montanide™ GEL01 PR (GEL01) and introduced Galectin-8 (Gal-8), a lectin considered a novel adjuvant due to its immunostimulatory effects, into the formulation. Animals were vaccinated with pCIgD, pCIgD with Gal-8 (pCIgD-Gal-8), pCIgD with Gal-8 and GEL01 (pCIgD-Gal-8-GEL01), or the control plasmid pCIneo. The immune response was first assessed in a mouse model and then in bovines. The results showed that combining Gal-8 and GEL01 with pCIgD modulated immune responses at both the humoral and cellular levels in both animal models. This study evaluates the efficacy of a DNA vaccine with Gal-8 and GEL01 as potential adjuvants to enhance immune protection against BoAHV-1.

Keywords: Adjuvant; Bovine alphaherpesvirus type-1; Bovine immune response; DNA vaccine; GEL01; Galectin-8; Murine model.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Some of the authors of this paper are authors of a relevant patent; see ref (Campetella and Tribulatti, 2023).

References

Publication types

MeSH terms

LinkOut - more resources